文献速递心胸血管麻醉

纤维蛋白原浓缩物在心血管手术中的应用:随机对照试验的荟萃分析

Fibrinogen Concentrate in Cardiovascular Surgery: A Meta-analysis of Randomized Controlled Trials.
PubMed 文献 · Anesth Analg · 2018-01-01

该系统评价与荟萃分析纳入8项成人心血管手术随机对照试验(n=597),比较围术期纤维蛋白原浓缩物与安慰剂或常规治疗。

要点

  • 围术期纤维蛋白原浓缩物未显著降低心血管手术成人患者全因死亡率。
  • 纤维蛋白原浓缩物显著减少异体红细胞输注需求(RR 0.64)。
  • 现有证据不足以支持或反对常规围术期使用纤维蛋白原浓缩物。

核心结论

  • 当前证据不足以支持或反对心血管手术患者常规围术期使用纤维蛋白原浓缩物。
  • 纤维蛋白原浓缩物可能减少高危或存在出血证据患者对异体血制品的需求,但未显示降低死亡风险或其他临床相关结局的明确优势。

研究设计与样本

  • 系统检索PubMed、Cochrane Library、Ovid MEDLINE、Embase、Web of Science和中国知网,检索日期为2017年1月15日,自动更新至2018年2月15日。
  • 纳入成人心血管手术中比较纤维蛋白原输注与任何其他对照(安慰剂/常规治疗或另一种活性对照)并报告至少1项预设临床结局的随机对照试验。
  • 共纳入8项随机对照试验,成人患者n=597,风险混合或高危。
  • 采用随机效应模型计算二分类变量的风险比和连续变量的加权均数差(95%CI)。
  • 预先计划按纤维蛋白原剂量和基线出血风险进行亚组分析。

主要发现

  • 其他临床结局未见显著差异。
  • 按纤维蛋白原剂量、输注起始时间、平均体外循环时间和旋转血栓弹力图/纤维蛋白原功量图使用进行的亚组分析均无显著交互作用(所有亚组交互P值均无统计学意义)。

临床怎么用

  • 对于高危或存在出血证据的心血管手术患者,纤维蛋白原浓缩物可能减少异体血制品输注需求。
  • 不应基于现有证据常规围术期使用纤维蛋白原浓缩物,需个体化评估获益与风险。

局限性

  • 现有随机对照试验中临床事件数量较少,需进一步设计良好、把握度充足且随访时间足够的研究来评估全因死亡率、卒中、心肌梗死、再手术和血栓栓塞事件。
  • 未来研究还应探讨相对于常规治疗的成本效益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postoperative bleeding remains a frequent complication after cardiovascular surgery and may contribute to serious morbidity and mortality. Observational studies have suggested a relationship between low endogenous plasma fibrinogen concentration and increased risk of postoperative blood loss in cardiac surgery. Although the transfusion of fibrinogen concentrate has been increasing, potential benefits and risks associated with perioperative fibrinogen supplementation in cardiovascular surgery are not fully understood. METHODS: PubMed, Cochrane Library, Ovid MEDLINE, Embase, Web of Science, and China National Knowledge Infrastructure were searched on January 15, 2017, with automated updates searched until February 15, 2018, to identify all randomized controlled trials (RCTs) of fibrinogen concentrate, whether for prophylaxis or treatment of bleeding, in adults undergoing cardiovascular surgery. All RCTs comparing fibrinogen infusion versus any other comparator (placebo/standard of care or another active comparator) in adult cardiovascular surgery and reporting at least 1 predefined clinical outcome were included. The random-effects model was used to calculate risk ratios and weighted mean differences (95% confidence interval [CI]) for dichotomous and continuous variables, respectively. Subgroup analyses by fibrinogen dose and by baseline risk for bleeding were preplanned. RESULTS: A total of 8 RCTs of fibrinogen concentrate in adults (n = 597) of mixed risk or high risk undergoing cardiovascular surgery were included. Compared to placebo or inactive control, perioperative fibrinogen concentrate did not significantly impact risk of all-cause mortality (risk ratio, 0.41; 95% CI, 0.12-1.38; I = 10%; P = .15). Fibrinogen significantly reduced incidence of allogeneic red blood cell transfusion (risk ratio, 0.64; 95% CI, 0.49-0.83; I = 0%; P = .001). No significant differences were found for other clinical outcomes. Subgroup analyses were unremarkable when analyzed according to fibrinogen dose, time of infusion initiation, mean cardiopulmonary bypass time, and rotational thromboelastometry/fibrinogen temogram use (all P values for subgroup interaction were nonsignificant). CONCLUSIONS: Current evidence remains insufficient to support or refute routine perioperative administration of fibrinogen concentrate in patients undergoing cardiovascular surgery. Fibrinogen concentrate may reduce the need for additional allogeneic blood product transfusion in cardiovascular surgery patients at high risk or with evidence of bleeding. However, no definitive advantage was found for reduction in risk of mortality or other clinically relevant outcomes. The small number of clinical events within existing randomized trials suggests that further well-designed studies of adequate power and duration to measure all-cause mortality, stroke, myocardial infarction, reoperation, and thromboembolic events should be conducted. Future studies should also address cost-effectiveness relative to standard of care.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Li JY, Gong J, Zhu F, et al. Fibrinogen Concentrate in Cardiovascular Surgery: A Meta-analysis of Randomized Controlled Trials. Anesth Analg. 2018. PMID: 29863608. doi:10.1213/ANE.0000000000003508

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。